research facilities for drug testing and analysis.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Sigma Aldrich Manufacturing LLC. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Sigma Aldrich Manufacturing LLC. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: June 17, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–15557 Filed 6–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated December 17, 2009, and published in the **Federal Register** on January 4, 2010 (75 FR 160), Mylan Technologies Inc., 110 Lake Street, Saint Albans, Vermont 05478, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Methylphenidate (1724)	II
Fentanyl (9801)	II

The company plans to import the listed controlled substances for analytical research and clinical trials.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Mylan Technologies Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Mylan Technologies Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: June 17, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–15556 Filed 6–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated March 16, 2010, and published in the **Federal Register** on March 24, 2010 (75 FR 14187), Meridian Medical Technologies, 2555 Hermelin Drive, St. Louis, Missouri 63144, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Morphine (9300), a basic class of controlled substance listed in schedule II.

The company manufactures a product containing morphine in the United States. The company exports this product to customers around the world, including in Europe. The company has been asked to ensure that its product sold to European customers meets standards established by the European Pharmacopeia, which is administered by the Directorate for the Quality of Medicines (EDQM). In order to ensure that its product will meet European specifications, the company seeks to import morphine supplied by EDQM to use as reference standards. This is the sole purpose for which the company will be authorized by DEA to import morphine.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Meridian Medical Technologies to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Meridian Medical Technologies to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: June 17, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–15555 Filed 6–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated March 16, 2010, and published in the **Federal Register** on March 24, 2010 (75 FR 14186), Roche Diagnostics Operations Inc., *Attn:* Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Alphamethadol (9605)	I
Cocaine (9041)	II
Ecgonine (9180)	II
Methadone (9250)	II
Morphine (9300)	II

The company plans to import the listed controlled substances for the manufacture of diagnostic products for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Roche Diagnostics Operations Inc. to

import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Roche Diagnostics Operations to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: June 17, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–15530 Filed 6–25–10; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

National Institute of Corrections

Solicitation for a Cooperative Agreement: Meetings of the Institutional Corrections Research Network and Two Subject Matter Experts Meetings on Correctional Research

AGENCY: National Institute of Corrections, U.S. Department of Justice.

ACTION: Solicitation for a cooperative agreement.

SUMMARY: The National Institute of Corrections (NIC) is soliciting proposals from organizations, groups, or individuals to enter into a cooperative agreement for an 18-month period to begin in September 2010. Work under this cooperative agreement will involve organizing four meetings—two annual meetings of the Institutional Corrections Research Network (ICRN) and two other meetings, one focusing on the research needs of jails and the other on a combined research agenda for prisons, jails, and community corrections.

NIC established ICRN in 2007 to promote the development of a stronger research infrastructure in corrections by bringing together agency-based researchers to discuss issues and share insights on the conduct of research in agencies that operate correctional institutions. The network members met annually from 2007–2009 to show examples of the research they were conducting for their agencies, identify new research directions, discuss how they make research relevant to their agency's mission, and share information and concerns about doing research in a correctional environment. ICRN is modeled after similar efforts sponsored by NIC that bring together corrections professionals from different sectors of corrections and by the Community Corrections Research Network, sponsored by the National Institute of Justice, which is made up of researchers working in community corrections agencies. ICRN represents NIC's ongoing commitment to assist correctional agencies as they work to become more evidence-based in their policies and practices, make greater use of outcome measures and performance standards, and incorporate data-driven approaches in their strategic planning and organizational development.

While the ICRN meetings have been very helpful to its members, two issues have emerged from their discussions and the meetings of other similar groups. One is the network's relative absence of researchers working in jails. Under this cooperative agreement, NIC will address this issue by (1) making a concerted effort to recruit jail researchers to participate in ICRN meetings and (2) hold a separate meeting focusing on the research needs of jails. A second issue concerns the lack of cross-discipline discussions among researchers working in state departments of corrections, in jails or jail systems, and in different parts of community corrections, such as pretrial, probation, and parole. The final meeting to be organized under this cooperative agreement will bring together researchers who focus on different aspects of corrections to have them develop a combined research agenda to address the problems that are common to them all.

DATES: Applications must be received by 4 p.m. (EDT) on Friday, July 23, 2010. Selection of the successful applicant and notification of review results to all applicants: September 30, 2010.

ADDRESSES: Mailed applications must be sent to Director, National Institute of Corrections, 320 First Street, NW., Room 5002, Washington, DC 20534. Applicants are encouraged to use Federal Express, UPS, or similar service to ensure delivery by the due date.

Hand delivered applications should be brought to 500 First Street, NW., Washington, DC 20534. At the front desk, call (202) 307–3106, extension 0 for pickup.

Faxed or e-mailed applications will not be accepted. Electronic applications can be submitted via *http://www.grants.gov.*

FOR FURTHER INFORMATION: A copy of this announcement can be downloaded from the NIC Web site at *http://www.nicic.gov/cooperativeagreements.*

All technical or programmatic questions concerning this announcement should be directed to Pamela Davison. She can be reached by calling 1–800–995–6423 ext 0484 or by e-mail at *pdavison@bop.gov.*

SUPPLEMENTARY INFORMATION: The recipient of the award under this cooperative agreement will organize and coordinate all logistical details for all four meetings—the two annual meetings of the Institutional Corrections Research Network (ICRN), plus the two other meetings on the research needs of jails and the combined research agenda for corrections. All expenses for these meetings will be provided out of the funding awarded under this agreement. The two ICRN meetings are each expected to last up to two days for up to 24 participants. The two additional meetings are expected to last one and a half days for up to 10 participants. NIC will identify the participants for each meeting, and it will also identify the location of the meetings based on the geographic distribution of the participants. The meetings will take place in the contiguous 48 states.

The recipient of this award will assist NIC in locating an appropriate venue and coordinating local arrangements at the site, including meeting rooms, food, and beverage services. The recipient will also assist participants in arranging travel and lodging and in reimbursing costs in conformity with Federal guidelines.

With input from NIC, the recipient will prepare each meeting agenda, participant lists, white papers, handouts, and supplementary materials; duplicate them in sufficient quantities; and deliver them to the venue. The recipient will also provide a note taker for each meeting.

Deliverables: By the end of the project, the recipient of this award will deliver the following products: (1) Each of the four meetings, (2) detailed notes of the proceedings of each meeting, including transcriptions of any other written material produced during the meeting, such as the contents of flip charts, (3) a summary report providing an overview of the meetings, their major themes, and any recommendations for the field.

Required Expertise: Successful applicants should have the